Search results for "Drug Combination"

showing 10 items of 197 documents

Comparison of the effect of low level laser therapy with alvogyl on the management of alveolar osteitis

2014

Background This study investigated the efficacy of low level laser therapy (LLLT) for managing alveolar osteitis (AO). Material and Methods Sixty patients with alveolar osteitis of mandibular third molars were randomly divided into three groups. In group 1, socket irrigation was followed by alvogyl placement, and the treatment was repeated 48 hours later. In group 2, socket was irradiated with a low power red laser for 3 consecutive days (200 mW, 30 seconds on each of the buccal and lingual surfaces and 30 seconds at the middle of the socket, 6 J per area). The subjects in group 3 underwent treatment with a low power infrared laser with the same parameters as group 2. A visual analogue scal…

AdultMaleMolarmedicine.medical_specialtyVisual analogue scalemedicine.medical_treatmentDry SocketDentistryOdontologíalaw.inventionYoung AdultRandomized controlled triallawEugenolOils Volatilepara-AminobenzoatesmedicineHumansProspective StudiesHydrocarbons IodinatedLow-Level Light TherapyProspective cohort studyGeneral DentistryLow level laser therapyAgedMorningbusiness.industryResearchMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryDrug CombinationsDry socketOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgeryOral SurgeryOsteitisbusiness
researchProduct

Cytological changes in the oral mucosa after use of a mouth rinse with alcohol. A prospective double blind control study

2012

Aim: The aim of this preliminary study was to detect cytological changes in the oral mucosa after using a mouth wash with alcohol. Material and Methods: A prospective double-blind, controlled study was performed, for 6 months. Group 1 consisted of 30 subjects who used a mouth rinse with 26.9% of alcohol [Listerine®] and Group 2 consisted of 30 subjects who used a mouth rinse with the same ingredients but with no alcohol. We obtained three cytological samples from the oral mucosa. The presence of cytological atypia, binucleation and karyorrhesis, and type of cells were studied. We also used a fluorescent in situ hybridization technique (FISH) in 15 samples in each group, for the micronucleus…

AdultMaleMouthwashesDentistryAlcoholDouble blindchemistry.chemical_compoundDouble-Blind MethodMouth rinseAtypiaHumansMedicineProspective StudiesOral mucosaProspective cohort studyGeneral DentistryOral Medicine and PathologyEthanolTerpenesbusiness.industrySignificant differenceMouth Mucosamedicine.diseaseSalicylatesDrug Combinationsmedicine.anatomical_structureOtorhinolaryngologychemistryFemaleResearch-ArticleSurgerybusinessMicronucleusMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

The effects of an amine fluoride/stannous fluoride and an antimicrobial host protein mouthrinse on supragingival plaque regrowth.

2004

BACKGROUND: Chlorhexidine (CHX)-containing mouthrinses are recommended as adjuncts to mechanical oral hygiene. The problem associated with side effects, however, has stimulated the search for alternative antiplaque agents. The aim of this study was to investigate the plaque inhibitory effects of two mouthrinses containing amine fluoride/stannous fluoride (ASF) and antimicrobial host proteins (lactoperoxidase, lysozyme and lactoferrin; LLL), respectively. METHODS: The study was an observer-masked, randomized 4x4 Latin square cross-over design balanced for carryover effects, involving 12 healthy volunteers in a 4-day plaque regrowth model. A 0.12% CHX mouthrinse and a saline solution served a…

AdultMaleORAL HYGIENE PRODUCTSmedicine.medical_treatmentLISTERINEDental PlaqueMouthwashesDentistryOral hygienePERIODONTAL-DISEASESStatistics Nonparametricchemistry.chemical_compoundGingivitisMedicineHumansFluorides TopicalSingle-Blind MethodLactoperoxidaseSalineVITALITYObserver VariationAnalysis of VarianceCross-Over Studiesbiologybusiness.industryLactoferrinGINGIVITISLactoperoxidaseChlorhexidineChlorhexidineAntimicrobialEFFICACYPREVENTIONDrug CombinationsLactoferrinchemistryCHLORHEXIDINE MOUTHRINSESbiology.proteinTin FluoridesPeriodonticsPatient ComplianceFemaleMuramidasemedicine.symptombusinessFluoridemedicine.drugMERIDOLJournal of periodontology
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

The Effects of an Essential Oil and an Amine Fluoride/Stannous Fluoride Mouthrinse on Supragingival Plaque Regrowth

2008

Background: The side effects of chlorhexidine (CHX) have stimulated the search for alternative antiplaque agents such as amine fluoride/stannous fluoride (ASF) and essential oils (EO). The aim of the study was to investigate the plaqueinhibiting effects of two commercially available mouthrinses containing ASF and EO, respectively. Methods: The study was an observer-masked, randomized, 5 · 5 Latin square cross-over design, balanced for carryover effects, involving 15 volunteers in a 4-day plaque regrowth model. A 0.12% CHX rinse and a saline solution served as positive and negative controls, respectively. On day 1, subjects received professional prophylaxis, suspended oral hygiene measures, …

AdultMalefluoride/therapeutic useDosemedicine.medical_treatmentDental PlaqueMouthwashesPainDentistryDental plaqueOral hygienelaw.inventionTaste Disorderschemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologichelawLatin squareDental plaque/prevention and controlOils VolatilemedicineHumansSingle-Blind MethodAminesSalineEssential oilCross-Over StudiesTerpenesbusiness.industryChlorhexidineDental Plaque IndexChlorhexidineessential oils/ therapeutic useoral hygienemedicine.diseaseSalicylatesDrug CombinationschemistryAnti-Infective Agents LocalTin FluoridesPeriodonticsFemaleMouth DiseasesbusinessFluoridemedicine.drugJournal of Periodontology
researchProduct

The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study

2013

SURGE 2, a large-scale, practice-based study in 10 countries, evaluated the effects of telmisartan alone or with hydrochlorothiazide (HCTZ) on morning (06:00 – 11:59) home blood pressure (HBP) control. Hypertensive patients (clinic blood pressure [BP] 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12.5 mg for 8 weeks. Treatment could be adjusted if clinic BP remained 140/90 mmHg. Clinic BP was measured in the morning prior to medication, and seated HBP monitoring was performed, three times per day, 2 days per week. A total of 25,882 patients were included (71% were previously using antihypertensives). There was a statistically signifi cant (all p 0.00…

AdultMalemedicine.medical_specialtyEveningAdolescentDiastoleBlood PressureBenzoatesYoung AdultHydrochlorothiazideInternal medicineInternal MedicinemedicineHumansProspective StudiesTelmisartanProspective cohort studyAdverse effectAntihypertensive AgentsMorningAgedAged 80 and overbusiness.industryHome blood pressure monitoring hydrochlorothiazide morning blood pressure control telmisartanGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedDrug CombinationsEndocrinologyBlood pressureHydrochlorothiazideAnesthesiaHypertensionBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

Aggressive Pharmacological Treatment for Reversing Malignant Bowel Obstruction

2004

Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also reverse malignant bowel obstruction. Fifteen consecutive advanced cancer patients with inoperable bowel obstruction received a combination of drugs including metoclopramide, octreotide, dexamethasone and an initial bolus of amidotrizoato. Recovery of intestinal transit was reported within 1-5 days in fourteen patients, who continued this treatment without presenting symptoms of bowel obstruction until death. This case series establishes that the combination of propulsive and antisecretive agents can act synergistically to allow a fast recovery of bowel transit without inducing unpleasant col…

AdultMalemedicine.medical_specialtyMetoclopramidemedicine.drug_classOctreotideGastroenterologyBolus (medicine)Gastrointestinal AgentsInternal medicineEdemamedicineHumansGeneral NursingDexamethasoneAgedPelvic NeoplasmsTerminal Carebusiness.industrydigestive oral and skin physiologyPalliative CareFecal impactionDrug SynergismRecovery of FunctionMiddle Agedmedicine.diseasedigestive system diseasesBowel obstructionDrug CombinationsAnesthesiology and Pain MedicineTreatment OutcomeAnesthesiaAbdominal NeoplasmsCorticosteroidAntiemeticsFemaleNeurology (clinical)medicine.symptombusinessIntestinal Obstructionmedicine.drug
researchProduct

Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fl…

2005

The safety and efficacy of early bacterial prophylaxis with piperacillin-tazobactam were prospectively evaluated in 51 autologous peripheral blood stem cell transplantation (PBSCT) recipients. The results were compared with those obtained in 51 control patients receiving oral fluoroquinolones in a retrospective matched-pair control study. Overall, 76% of the study group and 98% of the control group developed at least one febrile episode during neutropenia (P=0.002). Time from neutropenia to the first febrile episode (FFE) was significantly longer in the study group than in the control group (P=0.04). Once a febrile episode appeared, the duration of fever was significantly longer in cases th…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentFevermedicine.drug_classMatched-Pair AnalysisPremedicationAntibioticsPenicillanic AcidBacteremiaGram-Positive BacteriaTazobactamTransplantation AutologousInternal medicineAmphotericin BGram-Negative Bacteriapolycyclic compoundsmedicineHumansAntibacterial agentAgedPiperacillinTransplantationPeripheral Blood Stem Cell TransplantationHematologybusiness.industryHematologyBacterial InfectionsMiddle AgedSurgeryPiperacillin Tazobactam Drug CombinationPiperacillin/tazobactamChemoprophylaxisFemaleStem cellbusinessPiperacillinmedicine.drugFluoroquinolonesBone marrow transplantation
researchProduct

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

2006

Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions. Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In mult…

AdultMalemedicine.medical_specialtyOral anticoagulationGuidelineRisk AssessmentElectrocardiographyFibrinolytic AgentsRisk FactorsDrug CombinationAntithromboticmedicineHumansOutpatient clinicRisk factorMultivariate AnalysiStrokeRisk stratificationAgedAntithrombotic therapyFibrinolytic AgentFramingham Risk Scorebusiness.industryRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationStrokeDrug CombinationsMultivariate AnalysisPractice Guidelines as TopicEmergency medicinePhysical therapyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessCardioversionsRisk assessmentHumanEuropean Heart Journal
researchProduct